Oncopeptides AB (publ) (ONCO) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Oncopeptides Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.381 -- 00:00:07.367 Welcome to the Oncopeptides webcast for the first quarter of 2026. 00:00:07.450 -- 00:00:12.317 Please note the disclaimer regarding forward-looking statements. 00:00:12.317 -- 00:00:19.304 Today's presentation is led by myself, Sofia Hegis, and our CFO, Henrik Bergentoft. 00:00:19.707 -- 00:00:22.851 We delivered net sales of 25.4 00:00:22.851 -- 00:00:26.193 million SEC in Q1 2026, 00:00:26.557 -- 00:00:28.119 a 91% 00:00:28.119 -- 00:00:31.521 increase compared to Q1 2025. 00:00:31.739 -- 00:00:36.606 Following the rights issue we announced in conjunction with our last quarterly update, 00:00:36.606 -- 00:00:40.912 the company held a cash position of 205.2 million 00:00:40.912 -- 00:00:43.916 SEK by the end of Q1. 00:00:43.916 -- 00:00:48.984 We remain on track to reach positive cash flow by 2027. 00:00:48.984 -- 00:00:50.984 During 00:00:51.327 -- 00:00:56.514 the quarter, we announced and completed a rights issue of approximately 200 00:00:56.514 -- 00:01:01.593 million SEK. I would like to take this opportunity to thank 00:01:01.593 -- 00:01:03.635 all our shareholders, 00:01:03.635 -- 00:01:08.420 new and old, that choose to participate in the rights issue. 00:01:08.420 -- 00:01:13.065 I would also like to thank HealthCap, our main owner, for their continued support and 00:01:13.065 -- 00:01:15.725 trust in oncopeptides. 00:01:16.308 -- 00:01:21.373 We secured fast track designation for our window of opportunity clinical study in 00:01:21.373 -- 00:01:26.477 glioblastoma, which emphasizes the high unmet need for this very difficult to treat 00:01:26.477 -- 00:01:31.650 tumor. Additionally, we continued to underscore PEPAXTI's position 00:01:31.650 -- 00:01:35.394 in the treatment landscape through real-world data. 00:01:35.3...